Contact: Xochilt Maher
4501 Colorado Blvd
11 articles with Shire Plc
Pharma giant Takeda Pharmaceutical is looking to begin 2019 with a bang – closing its $62 billion acquisition of Shire plc by Jan. 8. This morning Takeda announced that it will hold an investor vote next month on the planned acquisition in order to swiftly move and finalize the deal.
As the acquisition of Shire by Takeda Pharmaceutical inches forward, global regulatory agencies are signing off on the deal. As the European Commission (EC) conducts a review of the deal, it hit a snag.
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Shire Announces Early Results Of The Previously Announced Cash Tender Offers For Certain Outstanding Notes
As of 5:00 p.m. New York City time, on September 7, 2018 (the "Early Tender Date"), the principal amounts of the Notes listed in the table below had been validly tendered and not validly withdrawn.
Shire plc announced today that the Offerors have commenced cash tender o?ers (collectively, the "Tender O?ers," and each o?er to purchase a series of notes individually, a "Tender O?er") to purchase up to $2,250,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of Baxalta's outstanding 2.875% Senior Notes due 2020, 3.600% Senior Notes due 2022, 4.000% Senior Notes due 2025 and 5.250% Senior Notes due 2045 and SAIIDAC's outstanding 3.200% Senior Notes due 2026
Shire launches screen responsibly, an eyelove® initiative dedicated to prioritizing eye health in a screen-saturated world
Shire plc (LSE: SHP, NASDAQ: SHPG) announced the launch of screen responsibly, its new educational initiative about the intersection between our screen use and eye health.
coreHEM Publishes Core Outcome Set for Hemophilia Clinical Trials; Prepares to Launch Next Phase of Work
The coreHEM initiative has announced the publication of a core outcome set for clinical trials of gene therapy in hemophilia.
LCS Group Sues Pharma Giant Shire for Breach of Contract & Fraud in Patent Dispute, Potential Damages “Into the Billions”
LCS Group, LLC (“LCS”) announced today that it has filed a federal lawsuit in the Southern District of New York against Shire Plc, Shire Development LLC, and Shire LLC (“Shire”) alleging Shire breached its contract with LCS and interfered with LCS’s prospective economic advantage, as well as perpetrated fraud [active case number for the complaint is 1:18-cv-02688-AT].
Notification of transactions by person discharging managerial responsibilities.
Shire reports 8% pro forma product sales and strong earnings growth resulting in record operating cash flow for full year 2017.
Shire is preparing to conduct Phase 3 trials investigating SHP647 for the treatment of moderately to severely active Crohn's disease in adults